Sugi Predict

Sugi Predict / Compounds / SCHEMBL3144797

SCHEMBL3144797

SCHEMBL3144797

CC(C)(C)OC(=O)CCn1cccn1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 2/20 0.45
▸ LMNA P02545 3/20 0.42
▸ POLB P06746 1/20 0.40
▸ KMT2A Q03164 2/20 0.37
▸ FDPS P14324 1/20 0.36
▸ GFER P55789 1/20 0.35
▸ DAO P14920 1/20 0.34
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ SCN10A Q9Y5Y9 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23666177 0.83 KDM4E (0.40) THRBLMNAKMT2AFDPSHDAC1
SCHEMBL14578736 0.81 THRB (0.51) THRBLMNAPOLBKMT2AFDPS
SCHEMBL10401539 0.80 THRB (0.47) THRBLMNAPOLBKMT2AFDPS
SCHEMBL30715075 0.80 THRB (0.50) THRBLMNAPOLB
SCHEMBL13086569 0.78 THRB (0.45) THRBLMNAPOLBKMT2AFDPS
SCHEMBL28230841 0.77 TDP1 (0.43) THRBLMNAKMT2AGFER
SCHEMBL412090 0.75 THRB (0.48) THRBLMNAPOLBKMT2AFDPS
SCHEMBL21995202 0.75 THRB (0.46) THRBLMNAKMT2A
SCHEMBL25969616 0.75 CPB2 (0.38) THRBLMNAKMT2A
SCHEMBL13096788 0.74 THRB (0.47) THRBLMNAPOLBKMT2AFDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3882252-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2025-11-19 — — EP disclosed
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 — — CN disclosed
EP-3882252-A1 BETA-LACTAMASE INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2021-09-22 — — EP disclosed
US-11008346-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2021-05-18 — — US disclosed
EP-3154989-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2021-03-24 — — EP disclosed
US-20200361962-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-11-19 — — US disclosed
CN-109988186-A Beta-lactamase inhibitor 维纳拓尔斯制药公司 2019-07-09 — — CN disclosed
CN-106687465-B β -lactamase inhibitor 维纳拓尔斯制药公司 2019-04-16 — — CN disclosed
US-9926336-B2 Beta-lactamase inhibitors VENATORX PHARMACEUTICALS (US) 2018-03-27 — — US disclosed
US-20170342092-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-30 — — US disclosed
US-20160264598-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-15 — — US disclosed
WO-2015191907-A1 BETA-LACTAMASE INHIBITORS VenatoRx Pharmaceuticals, Inc. (US) 2015-12-17 — — WO disclosed
US-20100135960-A1 ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-06-03 — — US disclosed
US-20100074863-A1 ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS ENANTA PHARMACEUTICALS, INC. 2010-03-25 — — US disclosed
US-20090326019-A1 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
US-20090060874-A1 BICYCLIC PYRROLIDINE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-03-05 — — US disclosed
US-20090053175-A1 SUBSTITUTE PYRROLIDINE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-02-26 — — US disclosed
US-20090022689-A1 C4-SPIRO-PYRROLIDINE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2009-01-22 — — US disclosed
US-20090004140-A1 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES ENANTA PHARMACEUTICALS, INC. 2009-01-01 — — US disclosed
WO-2009003009-A1 SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES ENANTA PHARMACEUTICALS, INC. (US) 2008-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008346-B2 Beta-lactamase inhibitors MGAM, GAA, LCT THRB 2487/4885LMNA 542/4885POLB 404/4885
US-20090326019-A1 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS ZC3HAV1, EIF2AK2, POLRMT THRB 4516/4885LMNA 3520/4885POLB 81/4885
US-20170342092-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT THRB 2487/4885LMNA 542/4885POLB 404/4885
US-20090004140-A1 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES EIF2AK2, RNGTT, POLR2E THRB 4215/4885LMNA 4122/4885POLB 60/4885
US-20090022689-A1 C4-SPIRO-PYRROLIDINE ANTIVIRALS ZC3HAV1, HAVCR2, HCCS THRB 3457/4885LMNA 2574/4885POLB 759/4885
US-20090053175-A1 SUBSTITUTE PYRROLIDINE DERIVATIVES POLRMT, EIF2AK2, NSUN2 THRB 4044/4885LMNA 3748/4885POLB 46/4885
US-20200361962-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT THRB 2487/4885LMNA 542/4885POLB 404/4885
US-20100074863-A1 ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS ZC3HAV1, POLRMT, EIF2AK2 THRB 4126/4885LMNA 3587/4885POLB 40/4885
US-20090060874-A1 BICYCLIC PYRROLIDINE DERIVATIVES EIF2AK2, ZC3HAV1, POLRMT THRB 4167/4885LMNA 3067/4885POLB 59/4885
US-20160264598-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT THRB 2487/4885LMNA 542/4885POLB 404/4885
US-20100135960-A1 ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES EIF2AK2, NSUN3, ACSS2 THRB 4379/4885LMNA 3344/4885POLB 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.